LitCovid-sample-docs

Documents (8) JSON TSV

source DB	source ID	text	size	updated at	# proj.	updated_at
PMC	7199903	Site-specific glycan analysis of the SARS-CoV-2 spike SARS-CoV-2 spike protein, elaborated Vaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trime	17.9 KB	2020-09-27	39	-
PMC	7205724	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids Highlights • IVIG, combined w	29.5 KB	2020-12-29	40	-
PMC	7228307	Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs FcγR and mAb immune therapy AM Chenoweth et al. Abstract Abstract The human fragment crystallizable (Fc)γ	60.9 KB	2020-09-27	37	-
PMC	7253482	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation Abstract Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zo	37 KB	2020-09-27	37	-
PMC	7361216	A sugar‐coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19 An Editorial Highlight for “Selective inhibition of	9.26 KB	2020-11-19	36	-
PMC	7441788	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19 J. SUN ET AL. POSTGRADUATE MEDICINE Abstract ABSTRACT Coronavirus Disease 2019 (COVID-19), caused by severe acu	42.1 KB	2020-09-27	37	-
PMC	7443692	Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor Abstract The SARS-CoV-2 betacoronavirus uses its highly glycosylated trimeric Spike protein to bind to the cell su	72.3 KB	2020-12-29	22	-
PMC	7556165	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives Abstract Angiotensin-converting enzyme 2 (ACE2) is related to ACE but turned out to counteract several pathophysiological actions o	77 KB	2020-12-29	28	-